Edition:
United Kingdom

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

117.60EUR
18 Apr 2019
Change (% chg)

€-3.00 (-2.49%)
Prev Close
€120.60
Open
€120.90
Day's High
€120.90
Day's Low
€117.60
Volume
93,864
Avg. Vol
100,609
52-wk High
€155.95
52-wk Low
€107.50

Select another date:

Mon, Feb 25 2019

Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 billion

PARIS French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion (£1 billion), the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases.

Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 billion

PARIS French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases.

UPDATE 2-Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 bln

* Takeover worth up to $1.31 billion (Adds share price reaction and analyst comment)

RPT-Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 bln

PARIS, Feb 25 French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases.

Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 bln

PARIS, Feb 25 French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases.

French pharma group Ipsen closes in on its next drug deals

LONDON French drugmaker Ipsen plans to bring in multiple new medicines through a series of transactions and sees the recent price drop of biotech stocks as increasing deal opportunities, its chief executive said on Wednesday.

French pharma group Ipsen closes in on its next drug deals

LONDON French drugmaker Ipsen plans to bring in multiple new medicines through a series of transactions and sees the recent price drop of biotech stocks as increasing deal opportunities, its chief executive said on Wednesday.

French pharma group Ipsen closes in on its next drug deals

LONDON, Nov 14 French drugmaker Ipsen plans to bring in multiple new medicines through a series of transactions and sees the recent price drop of biotech stocks as increasing deal opportunities, its chief executive said on Wednesday.

BRIEF-Ipsen Presents Real-World Pancreatic Cancer Data On ONIVYDE

* REPORTED ON SUNDAY REAL-WORLD PANCREATIC CANCER DATA ON ONIVYDE

Select another date: